Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

August 22, 2017

Study Completion Date

August 22, 2017

Conditions

Psoriasis Vulgaris

Interventions

DRUG

LEO 32731

LEO 32731 is being developed by LEO Pharma.

DRUG

Placebo

Placebo contains the same excipients in the same concentration, only lacking LEO 32731

Trial Locations (1)

Investigational Site, London